Matthew joined Cyagen in September 2025 as Vice President of Business Development and Strategy bringing extensive experience in driving growth, building strategic partnerships, and leading high-performing teams in the advanced therapies sector. Matthew’s previous roles include Chief Business Officer of Mendel Partners, Vice President of Business Development at ReciBioPharm and Chief Commercial Officer at VectorBuilder. Matthew holds a PhD in Biochemistry from Imperial College London and was a Group Leader at the Max-Planck Institute for Heart and Lung Research. Matthew's passion lies at the intersection of science and business, enabling innovative life science companies to accelerate growth, attract investment, and deliver transformative therapies to patients.

Dr. Benjamin Qu earned his Bachelor's and Master's in Biochemistry and Molecular Biology from Nanjing University and a PhD in Biology (Dr.rer.nat.) from the University of Heidelberg. Since 2020, he has been a postdoctoral researcher at the Paul-Ehrlich-Institut and now serves as Scientific Business Development Manager at Cyagen.

With over a decade of experience, he specializes in viruses, vaccines, and immunity, with expertise in preclinical models, genetically modified mice, and leading cross-functional teams in both academic and industry settings.